On October 3, 2025, the U.S. Food and Drug Administration (FDA) announced a prioritization pilot program for reviewing abbreviated new drug applications (ANDAs). ANDAs are submissions for generic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback